Share on StockTwits

Fluidigm (NASDAQ:FLDM) is set to issue its Q114 quarterly earnings data on Monday, May 5th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $22.91 million for the quarter.

Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.11. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $20.73 million. During the same quarter last year, the company posted ($0.08) earnings per share. Fluidigm’s revenue was up 33.1% compared to the same quarter last year. On average, analysts expect Fluidigm to post $-0.97 EPS for the current fiscal year and $-0.59 EPS for the next fiscal year.

Fluidigm (NASDAQ:FLDM) opened at 37.55 on Friday. Fluidigm has a one year low of $15.72 and a one year high of $49.46. The stock has a 50-day moving average of $40.55 and a 200-day moving average of $37.67. The company’s market cap is $1.047 billion.

A number of research firms have recently commented on FLDM. Analysts at Mizuho upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a research note on Tuesday, April 22nd. They now have a $50.00 price target on the stock, up previously from $43.00. On the ratings front, analysts at Leerink Swann upgraded shares of Fluidigm from a “market perform” rating to an “outperform” rating in a research note on Monday, April 14th. They now have a $52.00 price target on the stock, up previously from $45.00. Finally, analysts at Maxim Group raised their price target on shares of Fluidigm from $52.00 to $65.00 in a research note on Friday, March 21st. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $46.44.

Fluidigm Corporation (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems such as single-cell genomics, applied genotyping and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.